Abstract Library

#4600 Artificial intelligence in predicting neuroendocrine tumour (NET) outcomes: A model-based prognostic approach

Introduction: Neuroendocrine tumours (NETs) vary widely in clinical behaviour, complicating prognosis. Traditional models often struggle with accuracy due to the complexity of NETs. Artificial intelligence (AI) offers tools for enhanced prognostic precision by analysing complex datasets. This study explores an AI-driven approach to predict outcomes in NET patients at Cantonment General Hospital, Pakistan.

Conference:

Presenting Author: Fatima A

Authors: Fatima A,

Keywords: artificial intelligence, machine learning, Precision medicine, Personalised treatment,

#4586 Base on neuroendocrine tumour classification in CT imaging using pretrained vision transformers and data augmentation

Introduction: Neuroendocrine tumours (NETs) are a group of cancers that can be difficult to distinguish from other malignancies in CT imaging. Their diverse appearance often leads to diagnostic challenges, requiring advanced techniques to improve classification accuracy. Pretrained Vision Transformers (ViTs) have shown promise in medical image analysis, but additional methods are needed to enhance model robustness, particularly when dealing with complex and heterogeneous tumour characteristics.

Conference:

Presenting Author:

Authors: Li H, Tang Z, Ding Z, Chen Y, Li H,

Keywords: Vision transformers, Cancer Detection, Transfer Learning, Medical Image Analysis,

#4579 Real-world effectiveness of lanreotide autogel in patients with advanced gastroenteropancreatic neuroendocrine tumours with antigen Ki-67 proliferation index above and below 10%: The KINETICS study

Introduction: The somatostatin analogue lanreotide is an established treatment option for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with a Ki-67 proliferation index (Ki-67)

Conference:

Presenting Author: Vandamme T

Authors: Vandamme T, Gerard L, Del Olmo-Garcia M, de Mestier L, Kiesewetter B,

Keywords: effectiveness, gastroenteropancreatic neuroendocrine tumour, GEP-NET, Ki-67 proliferation index, Ki-67, lanreotide, somatostatin analogue, somatostatin, real-world,

#4571 Characterisation and prognostic impact of carcinoid syndrome in bronchial neuroendocrine tumours

Introduction: Metastatic bronchial neuroendocrine tumours (MBNET) are associated with carcinoid syndrome in 10 to 40% of cases. Characteristics of carcinoid heart disease (CHD) are poorly described.

Conference:

Presenting Author: Baudin E

Authors: Hescot S, Marret G, Hadoux J, Laboureau S, Haissaguerre M,

Keywords: bronchial NET, carcinoid syndrome, 5HIAA, carcinoid heart disease,

#4474 Follow-up 68Ga-DOTATATE PET/CT post resection of small bowel neuroendocrine neoplasia

Introduction: Surgery remains the mainstay of treatment for resectable neuroendocrine neoplasms (NENs). Post resection, guidelines suggest a risk-based approach to surveillance, with 3-6 monthly imaging based on tumour biology. However, there is a paucity of data regarding the timing of surveillance imaging for resected well-differentiated NEN.

Conference:

Presenting Author:

Authors: Sabahi Z, Chan D, Darbhamulla S, Mok C, Samra J,

Keywords: Neuroendocrine, 68Ga-DOTATATE PET/CT, Small bowel,